fda, glaxo warn of death due to anti-flu medic, page-9

I believe there will be more cases like this as treating medical staff see their patients dying.

GSK still sees more profit in vaccines, with money rolling in year after year, not really needing a pandemic. Ready IV Relenza and Lani availability would take away some of the pressure for governments to order vaccines. Why should GSK limit decades of ongoing profit by providing an effective product with less profit?

Take-overs of DS & Biota are certainly being considered to limit or prevent IV Relenza and Lani production. BTA take-over would be simple enough, but the list of major DS shareholders would give GSK directors some sleepless nights. Major pharma competitors may even join forces to limit the damage.


BTA in the next year could be a $10 share with even greater future upside. Despite HC enthusiasts, BTA could probably be bought today for around $1 billion. Hunter Hall and Alleron will likely be emotionally unattached. It is reasonable to think that nearly 20% would be in the bag from day one with price the only consideration.

For GSK, also read any major pharma like Roche.